FDA's New Expedited IND Pilot: What It Means for Drug Developers

The FDA wants to make it easier for certain drug developers to get to clinical trials faster. That's a big deal, especially for smaller biotech companies that don't have unlimited time, funding, or resources.

In September 2026, the FDA announced a new Expedited Investigational New Drug (IND) Pilot Program to explore ways to shorten the early stages of drug development.

It's an encouraging change, but there's something important to keep in mind.

A faster path through the regulatory process doesn't necessarily mean your drug is ready for clinical trials.

There's still a lot of scientific, analytical, and manufacturing work that needs to happen along the way.

What Is the FDA's New Expedited IND Pilot?

The FDA's Expedited IND Pilot Program is looking at ways to reduce the time it takes eligible drug developers to prepare for first-in-human clinical trials.

The initial program is limited, with approximately 8 - 10 sponsor and research institution pairs expected to participate.

Here's what we know:

• The program was announced September 15, 2026.

• Applications are due October 30, 2026.

• The FDA wants to explore a more efficient approach to early drug development.

• Scientific standards and patient safety requirements still apply.

This doesn't mean every drug developer will suddenly have a faster approval process. It's a pilot, and the FDA will use what it learns to evaluate future approaches.

However, this is still an exciting update because it could change how things are approved in the future.

Why Is This Interesting for Smaller Biotech Companies?

Getting a new drug into clinical trials is expensive and complicated. For smaller companies, even a few months of unexpected delays can create problems with funding, staffing, and development plans.

It's also easy to underestimate how much work happens before clinical trials can begin.

A company might have encouraging early research results but still need to figure out:

• Can we manufacture this consistently?

• What testing do we need to demonstrate quality?

• Will our manufacturing process work at a larger scale?

• What documentation does the FDA expect?

• Can we produce the materials needed for clinical trials?

These aren't questions you want to start asking right before submitting an IND.

We've talked about similar challenges in our article on what happens between research and commercialization.

The earlier you understand what's required, the easier it becomes to plan the next steps.

Faster Clinical Trials Still Require Manufacturing Readiness

This is where the FDA's announcement becomes particularly interesting to us.

We work with researchers and biotech companies on the scientific and manufacturing challenges that come with developing new products.

Often, that means figuring out how to take something that works in a research setting and make it reproducible, testable, and suitable for the next stage of development.

If regulatory timelines become shorter, companies may need to start some of that work earlier.

There are three areas we think deserve particular attention.

1. Manufacturing processes

Just because you can successfully make a material in a small laboratory batch doesn't mean you can manufacture it consistently at a larger scale.

Process development helps teams understand how manufacturing conditions affect the final product, what needs to be controlled, and what changes may be necessary as production increases.

2. Analytical testing

You need reliable information about what you're manufacturing.

Depending on the product, this could include identity testing, purity, impurity analysis, stability studies, and other quality measurements.

The goal is to have the right information available when decisions need to be made, rather than discovering gaps late in development.

3. CMC documentation

Chemistry, Manufacturing, and Controls (CMC) is a major part of preparing for an IND.

It covers information about how a drug substance or product is manufactured, tested, and controlled.

The specific requirements depend on the product and development stage, but waiting until the end to think about documentation can create unnecessary challenges.

For teams preparing to enter clinical development, our clinical trial material readiness checklist provides another useful place to start.

What Should Drug Developers Do Now?

Even if your company isn't participating in the FDA's pilot, it's a good opportunity to look at how you're preparing for clinical development.

Not every biotech company needs to build its own laboratory or hire a complete manufacturing team to address these needs.

Working with a contract development and manufacturing organization (CDMO) can give companies access to scientific expertise, analytical capabilities, and manufacturing resources as projects advance.

If you're exploring that option, we've also explained what a CDMO does and how one can support a startup.

Why We're Watching This at Parimer Scientific

One reason this FDA announcement caught our attention is that it connects directly to the work we do with our clients.

We help organizations work through technical challenges involving process development, analytical testing, manufacturing, and regulatory preparation.

We know how much planning goes into getting a product ready for its next stage, especially when a company is working with limited resources or an aggressive timeline.

A more efficient regulatory process could be a real advantage for drug developers. The key is making sure the scientific and manufacturing work can support that progress.

It's encouraging to see the FDA exploring ways to make drug development more efficient.

If your team is preparing for clinical development and needs support with any of these areas, connect with Parimer Scientific. We'd be happy to learn more about what you're working on.